Nice — below is a compact, source-backed market brief for the Photodynamic Therapy (PDT) Market with company references + the best public “values” available, plus the sections you asked for. I prioritized authoritative company filings and recent market reports. Citations (most load-bearing) follow each load-bearing paragraph.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Photodynamic Therapy market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Photodynamic Therapy market.

Read complete report at: https://www.thebrainyinsights.com/report/photodynamic-therapy-market-14601

Quick company references (major PDT players & published values / notes)

Photocure ASA — leading uro-oncology PDT player (Hexvix® / Cysview®). Photocure reported total revenues ≈ NOK 500–525 million (2023–2024) with Hexvix/Cysview representing the large majority (Hexvix/Cysview revenue ~NOK 444–488M in FY2023–2024). Useful for modelling PDT drug/device combined revenue in uro-oncology.
Biofrontera AG — developer/marketer of Ameluz® (PDT for actinic keratosis) and devices; reported total revenue ≈ €21.7M (2024) with evidence of growth in 2025 H1 (H1 2025 revenue ~€8.8M vs H1 2024 €7.2M). Good reference for dermatology PDT commercial performance.
Galderma (Metvix®) — major dermatology player that markets Metvix® (PDT photosensitizer) through its therapeutic dermatology franchise; Galderma reported Therapeutic Dermatology net sales ≈ US$780M in 2024 (PDT is one component of that franchise). Use Galderma to represent large-scale dermatologist channel adoption and commercial muscle.
Novartis / Bausch & Lomb (VISUDYNE® / Verteporfin) — VISUDYNE (verteporfin) remains a canonical PDT product in ophthalmology; device approvals and lasers (e.g., ML6710i) support the ophthalmic PDT segment.
Other notable companies / device & photosensitizer suppliers: Biofrontera (Ameluz® + device), ADVANZ Pharma (Photofrin®), Sun Pharmaceutical / DUSA (Levulan® Kerastick®), FotoMedex, Lumenis / Lumibird / Modulight (lasers & light sources), Biolitec (interstitial PDT) — many of these are listed in vendor lists across market reports. For several vendors, PDT sales are a sub-line inside larger dermatology/medical device revenues.

Market headline values (public estimates — multiple sources)

Several market reports estimate the global PDT market in the mid-2020s at roughly USD 4.5–5.5 billion, with forecasts to USD ~7–9+ billion by the early-to-mid 2030s depending on source and scope (some reports include only drugs, some include devices and services). Example estimates: Mordor: USD 5.11B (2025) → USD 7.43B (2030), CAGR ~7.8%; Precedence / MarketDataForecast / Transparency produce nearby baselines (CAGRs ~6–9% depending on endpoint and whether devices are included). Use a single vendor baseline when modelling to avoid double-counting (drugs vs devices).

Recent developments (2023–2025)

Broader clinical acceptance & regulatory activity — device approvals and combinations (e.g., ophthalmic laser approvals tied to VISUDYNE) and new clinical trials in oncology and dermatology have increased attention on PDT beyond traditional AK and superficial cancers.
Commercial progress by niche players — Photocure’s steady Hexvix/Cysview revenue growth and Biofrontera’s commercial recovery/expansion are examples of active commercialisation in different PDT niches (uro-oncology and dermatology respectively).

Drivers

Expanding indications — from dermatology (actinic keratosis, superficial BCC) into uro-oncology, ophthalmology, and investigational oncology uses (combination with immunotherapies).
Device improvements & integrated systems — new lasers/light sources and delivery systems make procedures faster and more precise (raising clinician adoption).
Nanotech & targeted photosensitizers — advanced formulations (nanoparticles, targeted carriers) improving selectivity and reducing off-target effects expand clinical potential.
Aging population & skin cancer detection programs — larger addressable population for dermatology PDT (AK, field cancerization).

Restraints

Heterogeneous market definitions (some reports separate drugs vs devices vs services) — this complicates consistent market sizing.
Competition from alternative therapies (topicals, surgical excision, cryotherapy, new systemic oncology drugs) and reimbursement variability (PDT can be clinic-based and reimbursement varies by country).
Technical limitations — penetration depth limits for many photosensitizers and need for repeat treatments may limit some oncology uses.

Regional segmentation analysis (high level)

North America — largest revenue share in many reports (strong clinical adoption, reimbursement, and oncology/derm clinics).
Europe — strong dermatology adoption (Biofrontera, Photocure market presence) and established uro-oncology PDT programs.
Asia-Pacific — fast growth potential driven by rising dermatology/aesthetic clinics and expanding oncology trials; penetration lags but accelerating.
Rest of world (Latin America, MENA, Africa) — mixed adoption; volume potential exists but constrained by reimbursement and specialist availability.

Emerging trends

Combination therapies (PDT + immunotherapy): growing clinical trials testing PDT as a primer for immune response.
Nanoparticle photosensitizers & targeted delivery — improved solubility, tumor targeting, and reduced systemic photosensitivity.
Portable / clinic-friendly light sources and fractionated protocols — expanding office-based use and patient convenience.

Top use cases

Dermatology — Actinic keratosis (AK), superficial basal cell carcinoma (sBCC), field cancerization.
Uro-oncology — diagnostic/theranostic use (Hexvix/Cysview) and bladder cancer management.
Ophthalmology — verteporfin PDT (choroidal neovascularization / selected AMD uses).
Investigational oncology — superficial tumor ablation and combination with systemic therapies.

Major challenges

Depth of light penetration & photosensitizer delivery for deep solid tumors.
Fragmented reimbursement & procedure coding (varies widely by country).
Market fragmentation (many small niche players) — harder for any single company to dominate unless they have broad portfolios or large dermatology/oncology distribution.

Attractive opportunities

Next-gen photosensitizers & nano-formulations that enable deeper/tumor-selective PDT (commercial and licensing opportunities).
Integrated device + drug offerings (turnkey systems for clinics) to simplify procurement and capture recurring consumable revenue.
Combination therapy trials (PDT + IO agents) creating new oncology label expansion and value.

Key factors of market expansion (summary)

Regulatory approvals and clinic-friendly devices enabling broader outpatient adoption.
Sustained commercial success by niche leaders (e.g., Photocure, Biofrontera, Galderma) proving repeatable revenue models for photosensitizers + light systems.
Scientific progress in photosensitizer chemistry and delivery (nanocarriers, targeting) enabling new indications.

If you’d like next steps, I can immediately do one of the following (pick one) and produce it now:

Build a spreadsheet (CSV/Excel) listing the top PDT companies above, their most relevant PDT product(s), and the public FY revenue values I can find (Photocure, Biofrontera, Galderma lines, etc.).
Produce a 1-page slide (PowerPoint) summarizing market size, CAGR (pick a baseline — I can use Mordor or Grand View), and the top 8 vendors with one-line values.
Normalize the market forecasts (choose one research baseline, e.g., Mordor Intelligence) and produce a 5-year revenue projection table (market size and device/drug splits) you can use for modelling.

Which one do you want me to produce right now?